Key points are not available for this paper at this time.
Although the supporting evidence for oncological benefits of therapeutic systemic agents with respect to metastatic sites is not yet strong enough to provide a recommendation in advanced or metastatic urothelial carcinoma, clinicians may take into account tumor organotropism only in discussion with the patient fully informed on the optimal treatment decision to be taken.
Building similarity graph...
Analyzing shared references across papers
Loading...
Mehdi Kardoust Parizi
Comprehensive Cancer Center Vienna
Akihiro Matsukawa
Jikei University School of Medicine
Kensuke Bekku
Okayama University
European Urology Oncology
Cornell University
The University of Texas Southwestern Medical Center
Université de Montréal
Building similarity graph...
Analyzing shared references across papers
Loading...
Parizi et al. (Sat,) studied this question.
synapsesocial.com/papers/69dc14992e12f42e2195512a — DOI: https://doi.org/10.1016/j.euo.2023.11.001
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: